Literature DB >> 19754766

Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?

G N Pongas1, R E Lewis, G Samonis, D P Kontoyiannis.   

Abstract

Mucormycosis (zygomycosis) is an uncommon infection that afflicts severely immunocompromised patients and those with poorly controlled diabetes mellitus. A recent increase in the incidence of mucormycosis at many transplant centres has been linked to the introduction and widespread use of voriconazole prophylaxis in these high-risk populations. However, it is not known if this association reflects a true epidemiological link or represents a marker of changing immunosuppression occurring in parallel with the evolution of transplant practices and immunosuppression strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19754766     DOI: 10.1111/j.1469-0691.2009.02988.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  30 in total

Review 1.  Sudden death in a patient with bone marrow transplant by a fungus among us.

Authors:  Lemuel Non; Joanna Paula Sta Cruz; Sherilyn Tuazon
Journal:  BMJ Case Rep       Date:  2014-11-12

2.  Changing epidemiology of human mycoses--China and beyond.

Authors:  S S Y Wong; K Y Yuen
Journal:  Mycopathologia       Date:  2011-04-20       Impact factor: 2.574

3.  Usefulness of molecular biology performed with formaldehyde-fixed paraffin embedded tissue for the diagnosis of combined pulmonary invasive mucormycosis and aspergillosis in an immunocompromised patient.

Authors:  Véronique Hofman; Abdelmajid Dhouibi; Catherine Butori; Bernard Padovani; Martine Gari-Toussaint; Dea Garcia-Hermoso; Michèle Baumann; Nicolas Vénissac; Gieri Cathomas; Paul Hofman
Journal:  Diagn Pathol       Date:  2010-01-08       Impact factor: 2.644

4.  PCR followed by electrospray ionization mass spectrometry for broad-range identification of fungal pathogens.

Authors:  Christian Massire; Daelynn R Buelow; Sean X Zhang; Robert Lovari; Heather E Matthews; Donna M Toleno; Raymond R Ranken; Thomas A Hall; David Metzgar; Rangarajan Sampath; Lawrence B Blyn; David J Ecker; Zhengming Gu; Thomas J Walsh; Randall T Hayden
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

Review 5.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

6.  Future directions in mucormycosis research.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis; Oliver Lortholary; Oliver Lotholary; Brad Spellberg; Georgios Petrikkos; Emmanuel Roilides; Emmanuel Roillides; Ashraf Ibrahim; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

7.  Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.

Authors:  Anne-Pauline Bellanger; Nathaniel D Albert; Russell E Lewis; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

8.  Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.

Authors:  Anastasia Wasylyshyn; Kathleen A Linder; Caroline G Castillo; Shiwei Zhou; Carol A Kauffman; Marisa H Miceli
Journal:  Mycopathologia       Date:  2020-01-14       Impact factor: 2.574

9.  Preexposure to Isavuconazole Increases the Virulence of Mucorales but Not Aspergillus fumigatus in a Drosophila melanogaster Infection Model.

Authors:  Sebastian Wurster; Russell E Lewis; Nathaniel D Albert; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

10.  Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.

Authors:  Russell E Lewis; Ronen Ben-Ami; Leyla Best; Nathaniel Albert; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2012-12-13       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.